Engelhart M
Department of Dermatology, Rigshospital, Copenhagen, Denmark.
Br J Dermatol. 1988 Dec;119(6):751-4. doi: 10.1111/j.1365-2133.1988.tb03498.x.
The efficacy of the 5-HT-2-receptor antagonist, ketanserin, in the treatment of Raynaud's phenomenon was assessed in a double-blind, placebo-controlled, crossover trial in nine patients with generalized scleroderma (GS). Each patient received ketanserin 20 mg or placebo three times a day in the 1st week and 40 mg ketanserin or placebo three times a day for the remaining 4 weeks, and was then crossed over for 5 weeks. Measurements were made of finger blood pressure and flow during a cold challenge test and patients recorded numbers of Raynaud's attacks. No significant improvement was found in reactions to cold provocation or in numbers of Raynaud's attacks during ketanserin treatment, but intolerable side-effects were common. Interactions with concomitant medication might be a possible explanation for this. We conclude that ketanserin in the dose given, is not effective in the treatment of Raynaud's phenomenon in GS.
在一项针对9名泛发性硬皮病（GS）患者的双盲、安慰剂对照交叉试验中，评估了5-羟色胺-2-受体拮抗剂酮色林治疗雷诺现象的疗效。在第1周，每位患者每天服用3次20毫克酮色林或安慰剂，在接下来的4周里，每天服用3次40毫克酮色林或安慰剂，然后交叉治疗5周。在冷激发试验期间测量手指血压和血流，并记录患者雷诺发作的次数。在酮色林治疗期间，对冷刺激的反应或雷诺发作次数均未发现显著改善，但难以耐受的副作用很常见。与同时服用的药物相互作用可能是对此的一种解释。我们得出结论，所给剂量的酮色林对治疗GS患者的雷诺现象无效。
